Compile Data Set for Download or QSAR
Report error Found 295 Enz. Inhib. hit(s) with all data for entry = 11452
TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617298(US11753403, Compound I-259)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617301(US11753403, Compound I-260)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617295(US11753403, Compound I-258)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617296(US11753403, Compound I-65)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617308(US11753403, Compound I-262)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617304(US11753403, Compound I-261)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617276(US11753403, Compound I-59)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617279(US11753403, Compound I-60)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617292(US11753403, Compound I-257)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617289(US11753403, Compound I-256)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617333(US11753403, Compound I-177)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617334(US11753403, Compound I-270)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617344(US11753403, Compound I-180)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617346(US11753403, Compound I-273)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617337(US11753403, Compound I-271)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617342(US11753403, Compound I-272)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617317(US11753403, Compound I-265)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617311(US11753403, Compound I-263)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617313(US11753403, Compound I-171)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617314(US11753403, Compound I-264)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617325(US11753403, Compound I-267)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617326(US11753403, Compound I-74)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617328(US11753403, Compound I-268)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617320(US11753403, Compound I-266)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617324(US11753403, Compound I-174)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617375(US11753403, Compound I-87)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617018(US11753403, Compound I-2)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617377(US11753403, Compound I-281)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617371(US11753403, Compound I-279)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM616977(US11753403, Compound I-1)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617374(US11753403, Compound I-280)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617383(US11753403, Compound I-283)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617098(US11753403, Compound I-100)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617104(US11753403, Compound I-101)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617058(US11753403, Compound I-3)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617380(US11753403, Compound I-282)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617382(US11753403, Compound I-190)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617358(US11753403, Compound I-275)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617352(US11753403, Compound I-274)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617368(US11753403, Compound I-278)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617407(US11753403, Compound I-329)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617408(US11753403, Compound I-330)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617409(US11753403, Compound I-331)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617410(US11753403, Compound I-332)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617403(US11753403, Compound I-324)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617404(US11753403, Compound I-325)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617122(US11753403, Compound I-108)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617405(US11753403, Compound I-326)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617406(US11753403, Compound I-327)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetEukaryotic translation initiation factor 4E [28-217](Human)
Pic Therapeutics

US Patent
LigandPNGBDBM617135(US11753403, Compound I-209)
Affinity DataIC50: 1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

Displayed 1 to 50 (of 295 total ) | Next | Last >>
Jump to: